



**Tepezza® (teprotumumab-trbw)**  
Effective 02/01/2023

<b>Plan</b>	<input checked="" type="checkbox"/> MassHealth (UPPL) <input type="checkbox"/> Commercial/Exchange	<b>Program Type</b>	<input checked="" type="checkbox"/> Prior Authorization
<b>Benefit</b>	<input type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit (NLX)		<input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
<b>Specialty Limitations</b>	This medication has been designated specialty and must be filled at a contracted specialty pharmacy.		
<b>Contact Information</b>	<b>Specialty Medications</b>		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	<b>Non-Specialty Medications</b>		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	<b>Medical Specialty Medications (NLX)</b>		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
<b>Exceptions</b>	N/A		

**Overview**

Tepezza® (teprotumumab-trbw) is a biologic that targets the insulin-like growth factor-1 (IGF-1) receptor that is indicated for the treatment of thyroid eye disease (TED) in adults.

No PA	Drugs that require PA
	Tepezza® (teprotumumab-trbw)

**Coverage Guidelines**

Authorization may be reviewed on a case by case basis for members who are new to the plan currently receiving treatment with requested medication and have not received in excess of 8 doses, excluding when the product is obtained as samples or via manufacturer’s patient assistance programs.

**OR**

Authorization may be granted for members when all the following criteria are met, and documentation is provided:

1. Appropriate diagnosis of thyroid eye disease
2. Member is ≥18 years of age
3. Prescriber is an endocrinologist or ophthalmologist, or consult notes from an endocrinologist or ophthalmologist are provided
4. Clinical activity score (CAS) ≥4 in at least one eye
5. Physician documentation of inadequate response, adverse reaction, or contraindication to glucocorticoids (*See Appendix A for requests that document that member is not a candidate for corticosteroids*)
6. Appropriate dosing (weight required)



### **Continuation of Therapy**

Reauthorization by physician may be granted for members who have not completed 6 months (8 doses) of treatment.

### **Limitations**

Approvals will be granted for a maximum of 8 doses (6 months) for one course of therapy per lifetime.

### **Appendix**

#### **Appendix A: Requests that document member is not a candidate for Corticosteroids**

- It may be reasonable to bypass corticosteroids depending on relative contraindications (e.g., obesity, elevated blood glucose) in patients for whom these would be compelling reasons to bypass steroids.
- If a prescriber is an ophthalmologist, the member has significant disease and the use of teprotumumab-trbw earlier in therapy may help avoid subsequent surgical interventions, this may be considered.

### **References**

1. Tepezza® [package insert]. Dublin (Ireland): Horizon Therapeutics; 2020 Jan.
2. FDA Approves TEPEZZA (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED) [press release on the internet]. Dublin (Ireland): Horizon Therapeutics; 2020 Jan 21 [cited 2021Nov2]. Available from: <https://ir.horizontherapeutics.com/news-releases/news-release-details/fda-approves-tepezzatm-teprotumumab-trbw-treatment-thyroid-eye>.
3. Davies TF, Burch HB. Clinical features and diagnosis of Graves' orbitopathy (ophthalmopathy). In: Basow DS (Ed). UpToDate [database on the internet]. Waltham (MA): UpToDate;2021[cited 2021 Nov 2]. Available from: <http://www.utdol.com/utd/index.do>.
4. American Thyroid Association. Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis [guideline on the internet]. Falls Church (VA): American Thyroid Association; 2016 [cited 2021Nov2]. Available from: <https://www.liebertpub.com/doi/pdfplus/10.1089/thy.2016.0229>.
5. European Thyroid Association. Guideline for the Management of Graves' Hyperthyroidism [guideline on the internet]. Altdorf, Germany: European Thyroid Association; 2018 [cited 2021Jun 2]. Available from: <https://www.karger.com/Article/Pdf/490384>
6. European Group on Graves' Orbitopathy. The 2021European Group on Graves' Orbitopathy Clinical Practice Guidelines for the medical Management of Graves' Orbitopathy [guideline on the internet]. 2021[cited 2021 Nov 22]. Available from:[https://ej.e.bioscientifica.com/configurable/content/journals\\$002feje\\$002f185\\$002f4\\$002feJE-21-0479.xml?t:ac=journals%24002feje%24002f185%24002f4%24002feJE-21-0479.xml](https://ej.e.bioscientifica.com/configurable/content/journals$002feje$002f185$002f4$002feJE-21-0479.xml?t:ac=journals%24002feje%24002f185%24002f4%24002feJE-21-0479.xml).

### **Review History**

09/16/2020- Created and Reviewed at Sept P&T Meeting. Effective 12/01/2020.  
11/16/2022 - Reviewed and Updated for Nov P&T. Matched MH UPPL. Separated out Comm/Exch vs MH. Effective 2/1/23.

### **Disclaimer**

AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.